Aliskiren 300 mg

DRUG5 trials

Sponsors

Novartis, Novartis Pharmaceuticals, Vanderbilt University Medical Center

Conditions

Heart FailureHigh Blood PressureHypertensionMyocardial IschemiaPost Acute Coronary Syndrome

Phase 2

Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome

CompletedNCT00409578

NovartisMyocardial Ischemia, Post Acute Coronary Syndrome

Start: 2007-02-28End: 2009-04-30Updated: 2011-04-19

A Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction Between Aliskiren and Furosemide in Patients With Heart Failure

CompletedNCT01125514

Novartis PharmaceuticalsHeart Failure

Start: 2010-05-31End: 2011-08-31Updated: 2012-09-10

Phase 3

Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study

CompletedNCT00706134

NovartisHypertension

Start: 2008-05-31End: 2009-04-30Updated: 2011-06-28

Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients Not Adequately Responding to Aliskiren Alone

CompletedNCT00777946

NovartisHypertension

Start: 2008-10-31End: 2009-05-31Updated: 2011-07-12

Phase 4

The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function

CompletedNCT03115853

Vanderbilt University Medical CenterHigh Blood Pressure

Start: 2009-06-30End: 2012-01-31Updated: 2017-08-25